Anabolic and Antiresorptive Osteoporosis Treatment: Trends, Costs, and Sequence in a Commercially Insured Population, 2003–2021

New anabolic medications (abaloparatide and romosozumab) were recently approved for osteoporosis, and data suggest that prescribing antiresorptive medications after a course of anabolic medications offers better outcomes. This study aimed to characterize prescription trends, demographics, geographic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wadhwa, Harsh, Wu, Janet Y, Lee, Jennifer S, Zygourakis, Corinna C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556263/
https://www.ncbi.nlm.nih.gov/pubmed/37808398
http://dx.doi.org/10.1002/jbm4.10800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556263/
https://www.ncbi.nlm.nih.gov/pubmed/37808398
http://dx.doi.org/10.1002/jbm4.10800

Ejemplares similares